Starpharma Holdings Limited (SPHRF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -9.63 Million AUD | 43.48% |
| 2023 | -17.04 Million AUD | -41.16% |
| 2022 | -16.63 Million AUD | 22.35% |
| 2021 | -21.42 Million AUD | -35.92% |
| 2020 | -15.76 Million AUD | -2.85% |
| 2019 | -15.32 Million AUD | -34.06% |
| 2018 | -11.43 Million AUD | 20.23% |
| 2017 | -14.89 Million AUD | 34.1% |
| 2016 | -21.74 Million AUD | -22.67% |
| 2015 | -17.72 Million AUD | -30.98% |
| 2014 | -13.53 Million AUD | -224.51% |
| 2013 | -4.17 Million AUD | 66.66% |
| 2012 | -12.5 Million AUD | -69.44% |
| 2011 | -7.38 Million AUD | -58.21% |
| 2010 | -4.66 Million AUD | -105.19% |
| 2009 | -2.27 Million AUD | 71.99% |
| 2008 | -6.09 Million AUD | -2.33% |
| 2007 | -5.91 Million AUD | -21.43% |
| 2006 | -6.53 Million AUD | 5.08% |
| 2005 | -6.88 Million AUD | -40.98% |
| 2004 | -4.88 Million AUD | 29.49% |
| 2003 | -6.92 Million AUD | 23.74% |
| 2002 | -8.69 Million AUD | -64.45% |
| 2001 | -5.52 Million AUD | -55.79% |
| 2000 | -3.54 Million AUD | -51.56% |
| 1999 | -2.33 Million AUD | 8.0% |
| 1998 | -2.54 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -3.49 Million AUD | -706.35% |
| 2024 Q1 | -433 Thousand AUD | 87.94% |
| 2024 Q2 | -4.38 Million AUD | 0.0% |
| 2024 FY | - AUD | 40.19% |
| 2024 Q4 | -3.49 Million AUD | 0.0% |
| 2023 Q3 | -3.6 Million AUD | 71.37% |
| 2023 Q4 | -10.88 Million AUD | -201.86% |
| 2023 Q1 | -4.03 Million AUD | 63.31% |
| 2023 Q2 | -12.59 Million AUD | -212.34% |
| 2023 FY | - AUD | -41.16% |
| 2022 Q3 | -3.75 Million AUD | 68.26% |
| 2022 Q4 | -10.99 Million AUD | -192.89% |
| 2022 FY | - AUD | 22.35% |
| 2022 Q1 | -4.14 Million AUD | 69.35% |
| 2022 Q2 | -11.82 Million AUD | -185.19% |
| 2021 Q3 | -4.57 Million AUD | 67.82% |
| 2021 Q1 | -5.14 Million AUD | 56.54% |
| 2021 Q2 | -14.2 Million AUD | -176.19% |
| 2021 FY | - AUD | -35.92% |
| 2021 Q4 | -13.52 Million AUD | -195.83% |
| 2020 Q3 | -4.33 Million AUD | 50.03% |
| 2020 Q1 | -2.86 Million AUD | 71.34% |
| 2020 Q4 | -11.83 Million AUD | -172.81% |
| 2020 Q2 | -8.68 Million AUD | -203.25% |
| 2020 FY | - AUD | -2.85% |
| 2019 Q1 | -3.55 Million AUD | -82.38% |
| 2019 Q4 | -9.99 Million AUD | -191.89% |
| 2019 FY | - AUD | -34.06% |
| 2019 Q3 | -3.42 Million AUD | 3.74% |
| 2019 Q2 | -3.55 Million AUD | 0.0% |
| 2018 Q1 | -3.03 Million AUD | 9.64% |
| 2018 Q4 | -1.94 Million AUD | 0.0% |
| 2018 FY | - AUD | 20.23% |
| 2018 Q3 | -1.94 Million AUD | 35.82% |
| 2018 Q2 | -3.03 Million AUD | 0.0% |
| 2017 Q3 | -3.31 Million AUD | 15.97% |
| 2017 Q2 | -3.94 Million AUD | 0.0% |
| 2017 Q1 | -3.94 Million AUD | 16.22% |
| 2017 FY | - AUD | 34.1% |
| 2017 Q4 | -3.36 Million AUD | -1.46% |
| 2016 Q4 | -4.7 Million AUD | 22.71% |
| 2016 Q3 | -6.08 Million AUD | -27.31% |
| 2016 Q2 | -4.78 Million AUD | 0.0% |
| 2016 Q1 | -4.78 Million AUD | 2.04% |
| 2016 FY | - AUD | -22.67% |
| 2015 FY | - AUD | -30.98% |
| 2015 Q4 | -4.88 Million AUD | 0.0% |
| 2015 Q3 | -4.88 Million AUD | -22.66% |
| 2015 Q2 | -3.98 Million AUD | 0.0% |
| 2015 Q1 | -3.98 Million AUD | 6.39% |
| 2014 Q2 | -2.51 Million AUD | 0.0% |
| 2014 FY | - AUD | -224.51% |
| 2014 Q4 | -4.25 Million AUD | 0.0% |
| 2014 Q3 | -4.25 Million AUD | -69.08% |
| 2014 Q1 | -2.51 Million AUD | -75.04% |
| 2013 Q3 | -1.43 Million AUD | -121.51% |
| 2013 Q4 | -1.43 Million AUD | 0.0% |
| 2013 FY | - AUD | 66.66% |
| 2013 Q1 | -648.5 Thousand AUD | 0.0% |
| 2013 Q2 | -648.5 Thousand AUD | 0.0% |
| 2012 FY | - AUD | -69.44% |
| 2011 FY | - AUD | -58.21% |
| 2010 FY | - AUD | -105.19% |
| 2009 FY | - AUD | 71.99% |
| 2008 FY | - AUD | -2.33% |
| 2007 FY | - AUD | -21.43% |
| 2006 FY | - AUD | 5.08% |
| 2005 FY | - AUD | -40.98% |
| 2004 FY | - AUD | 29.49% |
| 2003 FY | - AUD | 23.74% |
| 2002 FY | - AUD | -64.45% |
| 2001 FY | - AUD | -55.79% |
| 2000 FY | - AUD | -51.56% |
| 1999 FY | - AUD | 8.0% |
| 1998 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 86.441% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -62.458% |
| SQZ Biotechnologies Company | -64.14 Million USD | 84.983% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 44.548% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 110.243% |
| Mesoblast Limited | -62.38 Million USD | 84.562% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -527.063% |
| Genus plc | 73.7 Million USD | 113.069% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -45.685% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -171.554% |
| Marizyme, Inc. | -34.28 Million USD | 71.903% |
| ContraFect Corporation | -64.99 Million USD | 85.181% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -9.804% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -112.806% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -587.113% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -264.235% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -314.49% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1759.294% |
| Accustem Sciences Inc. | -3.74 Million USD | -157.099% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 80.028% |
| EV Biologics, Inc. | -1.26 Million USD | -660.142% |
| Q BioMed Inc. | -617.62 Thousand USD | -1459.515% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 369.653% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1423.072% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -321.626% |
| Biomind Labs Inc. | -1.03 Million USD | -831.034% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 197.519% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -34.501% |
| Skye Bioscience, Inc. | -13.54 Million USD | 28.902% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -547.568% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -38428.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -147.971% |
| IMV Inc. | -35.52 Million USD | 72.885% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 39.306% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -284.978% |
| GB Sciences, Inc. | -1.41 Million USD | -578.365% |
| Alpha Cognition Inc. | -9.7 Million USD | 0.758% |
| HST Global, Inc. | -5303.00 USD | -181533.038% |
| CSL Limited | 4.78 Billion USD | 100.201% |
| Halberd Corporation | -74.27 Thousand USD | -12867.326% |
| Enzolytics Inc. | -2.12 Million USD | -353.905% |
| Resverlogix Corp. | -11.74 Million USD | 17.97% |
| Affymax, Inc. | -14.29 Million USD | 32.62% |
| SYBLEU INC | -141.57 Thousand USD | -6703.653% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -214.461% |
| argenx SE | -216.02 Million USD | 95.541% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 82.595% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 891.454% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -542.602% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2642.471% |
| AVAX Technologies, Inc. | -6.11 Million USD | -57.575% |
| Zenith Capital Corp. | -8.6 Million USD | -11.922% |
| Genscript Biotech Corporation | -248.71 Million USD | 96.127% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -55189.593% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -293.712% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -5371.97% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 75.699% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -233.019% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -820.567% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 143348.067% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -450.4% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -401.429% |
| BioStem Technologies, Inc. | -7.55 Million USD | -27.515% |
| ONE Bio Corp. | 13.61 Million USD | 170.756% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -5218.961% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -368.255% |
| Agentix Corp. | -1.37 Million USD | -602.166% |
| LadRx Corporation | 412.28 Thousand USD | 2436.259% |
| Cell Source, Inc. | -4.27 Million USD | -125.44% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -2522.944% |
| Regen BioPharma, Inc. | 1.46 Million USD | 757.046% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -928.018% |
| NovAccess Global Inc. | -1.03 Million USD | -830.811% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 208.789% |
| Itoco Inc. | -1.86 Million USD | -415.357% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2437.274% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -763.082% |
| Kadimastem Ltd | -2.62 Million USD | -267.02% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -3927.598% |
| CytoDyn Inc. | -18.02 Million USD | 46.575% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -12087.931% |
| Mobile Lads Corp. | -2.24 Million USD | -329.778% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -78663.595% |
| Qrons Inc. | -40.08 Thousand USD | -23931.337% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -1883.207% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 1926.204% |
| Rebus Holdings, Inc. | -951 Thousand USD | -912.829% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -806.959% |
| International Stem Cell Corporation | 202 Thousand USD | 4868.317% |
| Bioxytran, Inc. | -3.82 Million USD | -152.137% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -18197.872% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -291.237% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 73.147% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -21304.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -251.79% |
| Neutra Corp. | -181.24 Thousand USD | -5214.295% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 52.22% |
| PureTech Health plc | -11.62 Million USD | 17.158% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 52.217% |
| IXICO plc | -707 Thousand USD | -1262.376% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -25.335% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 80.077% |
| CSL Limited | 4.73 Billion USD | 100.204% |
| Cellectis S.A. | -92.63 Million USD | 89.602% |